Cogstate Limited (CGS.AX)
Cogstate Limited operates in the Medical - Healthcare Information Services industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $2.69, down 2.18% on the session, giving a market capitalisation of $457.1M. Its beta of 0.20 implies it has historically moved less than the broad market.
Melbourne, Australia-based Cogstate Limited, established in 1999, is a neuroscience technology company specializing in computerized cognitive assessments and digital solutions for clinical outcome evaluations. Its comprehensive suite of cognitive services includes project and data management, scientific consulting, statistical analysis, procurement of assessment scales, rater training, and monitoring solutions. The company operates through two distinct divisions. The Clinical Trials segment delivers technology and support services designed to measure the impact of diseases, pharmaceuticals, medical devices, or other interventions on human participants in clinical studies, primarily serving pharmaceutical and biotechnology clients. Concurrently, its Healthcare segment offers Cognigram, a system facilitating regular and standardized testing to assist primary care physicians and hospitals in the early identification of cognitive decline. By June 30, 2022, Cogstate had participated in an estimated 1,800 academic research initiatives.
Cogstate Limited is most often compared with the following Healthcare names: